Regulatory compliance – Page 30

System access controls weak during validation lifecycle – 21 CFR Part 11 compliance gaps

Addressing Weaknesses in System Access Controls During the Validation Lifecycle In the fast-paced pharmaceutical environment, compliance with 21 CFR Part 11 is critical. However, weaknesses in system access controls can…

Validation gaps identified during system upgrades – regulatory deficiency risk

Addressing Validation Gaps Identified During System Upgrades to Mitigate Regulatory Deficiency Risks Pharmaceutical manufacturing is fraught with challenges, particularly when it comes to validation and regulatory compliance during system upgrades.…

GLP study documentation gaps during internal audit – alignment with OECD principles

“`html Addressing GLP Study Documentation Gaps During Internal Audits in Accordance with OECD Principles Internal audits are crucial for identifying compliance gaps related to Good Laboratory Practices (GLP) and ensuring…

Record retention failures during system operation – 21 CFR Part 11 compliance gaps

A Comprehensive Playbook for Addressing Record Retention Failures in Pharmaceutical Systems Record retention failures pose significant challenges during system operation, especially in relation to compliance with 21 CFR Part 11.…

Incomplete validation lifecycle during system upgrades – CAPA and revalidation strategy

“`html Managing Incomplete Validation Lifecycle During System Upgrades: A Comprehensive Playbook In the dynamic environment of pharmaceutical manufacturing, incomplete validation lifecycles during system upgrades can lead to compliance failures, resulting…

System access controls weak during system upgrade – preventing repeat Part 11 findings

Addressing Weak System Access Controls During Upgrades to Prevent Part 11 Findings The pharmaceutical industry is continuously advancing, particularly with the integration of electronic recordkeeping systems. However, these upgrades can…

Validation gaps identified during lifecycle management – inspection evidence expectations

Addressing Validation Issues in Pharmaceutical Lifecycle Management for Enhanced Inspection Readiness Validation is a critical component of effective pharmaceutical manufacturing, ensuring that processes and products meet regulatory standards and quality…

Electronic signatures misused during system upgrade – risk-based ERES remediation

Addressing Misuse of Electronic Signatures During System Upgrades: A Regulatory Playbook The use of electronic signatures (e-signatures) is a fundamental aspect of regulatory compliance in pharmaceutical manufacturing, especially during system…

Validation gaps identified during system upgrades – preventing repeat validation findings

Addressing Validation Gaps Identified During System Upgrades for Optimal Compliance In the fast-evolving landscape of pharmaceutical manufacturing, system upgrades are a necessity but often result in validation gaps that can…

Archival process non-compliant during sponsor oversight – evidence package inspectors expect

Addressing Non-Compliance in Archival Processes During Sponsor Oversight In the highly regulated pharmaceutical environment, the pivotal role of archival processes cannot be emphasized enough. These processes ensure that data integrity…

Record retention failures during system upgrade – CAPA and revalidation strategy

Strategies for Managing Record Retention Failures During System Upgrades In the ever-evolving landscape of pharmaceutical manufacturing, the integrity of electronic records is paramount. Record retention failures during a system upgrade…

Requalification overdue during site expansion – regulatory deficiency risk

Addressing Requalification Issues during Site Expansion to Mitigate Regulatory Risks As pharmaceutical manufacturing facilities expand, the urgency to maintain Good Manufacturing Practice (GMP) compliance increases, particularly concerning validation and requalification…